Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 12-16

  Waller, Lynsay L ^a   Miller, Antonius A ^a   Petty, W Jeffrey ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Biomarkers; Erlotinib; Hepatic metabolism; Pharmacology; Smoking

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; K RAS PROTEIN; KI 67 ANTIGEN; PLACEBO;

AREA UNDER THE CURVE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TUMOR LEVEL; ENZYME INHIBITION; GENE MUTATION; HUMAN; INDIVIDUALIZATION; INHIBITION KINETICS; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SMOKING HABIT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SMOKING CESSATION; TUMOR MARKERS, BIOLOGICAL;

EID: 71549117604     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.014     Document Type: Review

References (26)

1. Shepherd F., Rodrigues J., Ciuleanu T., Tan E., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
2. Hughes A., O'Brien M., Petty W., Chick J., Rankin E., Woll P., et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27 (2009) 1220-1226
3. Petty W., Dragnev K., Memoli V., Ma Y., Desai N., Biddle A., et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 10 (2004) 7547-7554
4. Moyer J., Barbacci E., Iwata K., Arnold L., Bowman B., Cunningham A., et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57 (1997) 4838-4848
5. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65 (2005) 9455-9462
6. Miller A., Murry D., Owzar K., Hollis D., Lewis L., Kindler H., et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25 (2007) 3055-3060
7. Ling J., Fettner S., Lum B., Riek M., and Rakhit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 19 (2008) 209-216
8. Hamilton M., Wolf J., Rusk J., Beard S., Clark G., Witt K., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12 (2006) 2166-2171
9. Kroon L. Drug interactions with smoking. Am J Health-Syst Pharm 64 (2007) 1917-1921
10. Massarelli E., Varella-Garcia M., Tang X., Xavier A., Ozburn N., Liu D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 13 (2007) 2890-2896
11. Zhu C., da Cunha Santos G., Ding K., Sakurada A., Cutz J., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21. J Clin Oncol 26 (2008) 4268-4275
12. Riely G., Kris M., Rosenbaum D., Marks J., Li A., Chitale D., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14 (2008) 5731-5734
13. Pham D., Kris M., Riely G., Sarkaria I., McDonough T., Chuai S., et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinoma. J Clin Oncol 24 (2006) 1700-1704
14. Marks J., Broderick S., Zhou Q., Chitale D., Li A., Zakowski M., et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3 (2008) 111-116
15. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
16. Cortes-Funes H., Gomez C., Rosell R., Valero P., Garcia-Giron C., Velasco A., et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16 (2005) 1081-1086
17. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
18. Cappuzzo F., Hirsch F., Rossi E., Bartolini S., Ceresoli G., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
19. Han S., Kim T., Hwang P., Jeong S., Kim J., Choi I., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
20. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
21. Eberhard D., Johnson B., Amler L., Goddard A., Heldens S., Herbst R., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
22. Mitsudomi T., Kosaka T., and Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11 (2006) 190-198
23. Gridelli C., Rossi A., and de Marinis F. Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT). Lung Cancer (2009) [Epub ahead of print]
24. Goodin S. Erlotinib: optimizing therapy with predictors of response. Clin Cancer Res 12 (2006) 2961-2963
25. Kumar A., and Wakelee H. Second- and third-line treatments in non-small cell lung cancer. Curr Treat Options Oncol 7 (2006) 37-49
26. Li J., Zhao M., He P., Hidalgo M., and Baker S. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13 (2007) 3731-3737